Current medical news and unique business news for anyone who cares about the healthcare industry.
Obama’s State of the Union address challenge: Talk about healthcare reform – but not too much.
Pitfalls of aging doctors. One-third of physicians are older than 65, the rate of disciplinary actions for older physicians is nearly five times that of younger doctors and there’s a concern there aren’t enough safeguards to monitor declining skills as physicians age.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
PerkinElmer enters gene sequencing. Via Forbes’ The Medicine Show: “Rather than compete with makers of big DNA sequencing machines, PerkinElmer is creating a service business that will allow researchers to get human genetic data without owning their own DNA sequencers or high-powered supercomputers.”
$4B in healthcare fraud. The federal government said it recovered $4 billion, largely from what it referred to as Medicare fraud.
Viibyrd FDA approval. Clinical Data wins approval for its antidepressant, which includes among its benefits little to no impact on sex drive. The company is already predicting a $1 billion drug.
Good news for Abbott’s RX Acculink. Abbott Laboratories wants its carotid stent approved for a broader array of patients, and indications are the U.S. Food and Drug Administration will allow it.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
HIMSS swarm. Nearly 30,000 are planning to attend the mega Health IT conference.
Dealflow and more. Cancer vaccine developer Inovio raised $24 million; Pfizer extends a tender offer to King Pharmaceuticals; Nektar Therapeutics raises $220 million; and Amgen buys cancer drugmaker Biovex for $425 million.
Bad news for obesity device industry. McDonalds is raising its prices.
